Sorted By Test Name - Mayo Medical Laboratories

HL15O
60348
HLA57
89346
An interpretive report will be provided.
Clinical References: 1. Man CB, Kwan P, Baum L, et al: Association between HLA-B*1502 allele
and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007;40:1015-1018 2.
Chung WH, Hung SL, Hong HS, et al: Medical genetics: a marker for Stevens-Johnson syndrome. Nature
2004;428:486 3. Hung SL, Chung WH, Jee SH, et al: Genetic susceptibility to carbamazepine-induced
cutaneous adverse drug reaction. Pharmacogenet Genomics 2006;16:297-306 4. Cox ST, McWhinnie AJ,
Robinson J, et al: Cloning and sequencing full-length HLA-B and -C genes. Tissue Antigens
2003;61:20-48 5. Hung, Shuen-Iu. Chung, Wen-Hung. Liu, Zhi-Sheng. Chen et al: Common risk allele in
aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han
Chinese. Pharmacogenomics. 2010;11:349-356
HLA-B 1502 Genotype, Carbamazepine Hypersensitivity, Saliva
Clinical Information: Clinical studies have demonstrated associations between some HLA genotypes
and drug-induced adverse skin reactions. The presence of the HLA-B*1502 allele increases the risk of
developing toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS), a milder form of TEN.
The frequency of the HLA-B*1502 allele varies throughout Asia: 10% to 15% frequency in Chinese, 2%
to 4% frequency in Southeast Asians, including Indians, and